Harmony Forms Inhaled Insulin JV in China with Dongbao Pharma

Harmony Biopharm, a Hong Kong company that in-licensed Asia rights to Dance Biopharm's inhaled insulin product, formed a JV with Dongbao Pharma to commercialize the product in China. The JV will be capitalized with $11 million. Dongbao, an insulin specialist, has deep knowledge of Dance's inhaled insulin product because it manufactures the product for Dance. Dance 501 is comprised of an inhaler and a liquid insulin formulation to keep the costs about the same as an insulin pen device. More details.... Share this with colleagues: // //